Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26712026 | 0.86 | — | — | |
| SCHEMBL24044983 | 0.85 | — | — | |
| SCHEMBL25897933 | 0.84 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL18583240 | 0.82 | GRM4 (0.33) | GRM4 | |
| SCHEMBL24571110 | 0.79 | SMPD1 (0.31) | — | |
| SCHEMBL24906756 | 0.78 | GRM4 (0.31) | GRM4 | |
| SCHEMBL21917242 | 0.78 | GRM4 (0.31) | GRM4 | |
| SCHEMBL19772674 | 0.78 | GRM4 (0.31) | GRM4 | |
| SCHEMBL805401 | 0.76 | ALDH1A1 (0.38) | GRM4 | |
| SCHEMBL18714174 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692079-B2 | 2-dimensional MXene particle surface-modified with functional group containing saturated or unsaturated hydrocarbon, preparation method thereof and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-07-04 | — | — | US | disclosed |
| US-20230129118-A1 | PHYTOSPHINGOSINE DERIVATIVES AS ADJUVANTS IN IMMUNE STIMULATION | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-04-27 | — | — | US | disclosed |
| EP-3175033-B1 | COMPOSITIONS FOR TREATMENT OF FIBER MATERIALS | HUNTSMAN TEXTILE EFFECTS GERMANY GMBH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220409612-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LTD (GB) | 2022-12-29 | — | — | US | disclosed |
| WO-2021255287-A1 | PHYTOSPHINGOSINE DERIVATIVES AS ADJUVANTS IN IMMUNE STIMULATION | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-12-23 | — | — | WO | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021212638-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-28 | — | — | WO | disclosed |
| WO-2012082995-A1 | OLIGOMER-CONTAINING HYDANTOIN COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-21 | — | — | WO | disclosed |
| US-8143366-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2012-03-27 | — | — | US | disclosed |
| US-8063015-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-20110227002-A1 | AROMATIC IMIDE-BASED DISPERSANT FOR CARBON NANOTUBES AND CARBON NANOTUBE COMPOSITION COMPRISING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-09-22 | — | — | US | disclosed |
| US-20100081782-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | EKWURIBE NNOCHIRI N | 2010-04-01 | — | — | US | disclosed |
| US-20100048456-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2010-02-25 | — | — | US | disclosed |
| US-7625995-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2009-12-01 | — | — | US | disclosed |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| WO-2007137260-A2 | PREPARATION OF POLYMER CONJUGATES OF VLA-4 ANTAGONISTS VIA A MITSUNOBU' S REACTION | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007102705-A1 | ANION RECEPTOR AND ELECTROLYTE USING THE SAME | KIM HEE JUNG (KR) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | GRM4 4728/4885MAPK1 2843/4885 |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | ALK, AOX1, OGFR | GRM4 1323/4885MAPK1 3153/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | GRM4 4728/4885MAPK1 2843/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | GRM4 3278/4885MAPK1 3202/4885 |
| US-20110227002-A1 | AROMATIC IMIDE-BASED DISPERSANT FOR CARBON NANOTUBES AND CARBON NANOTUBE COMPOSITION COMPRISING THE SAME | EWSR1, NES, CENPE | GRM4 4542/4885MAPK1 2879/4885 |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | TEK, TEKT1, EPCAM | GRM4 2716/4885MAPK1 3404/4885 |
| US-20230129118-A1 | PHYTOSPHINGOSINE DERIVATIVES AS ADJUVANTS IN IMMUNE STIMULATION | UGCG, PA2G4, IL4 | GRM4 260/4885MAPK1 2021/4885 |
| US-20220409612-A1 | TREATMENT OF CANCER | DDX1, CDC73, CBX2 | GRM4 4052/4885MAPK1 4449/4885 |
| US-20100048456-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | GRM4 2865/4885MAPK1 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.